NCT02359617View on ClinicalTrials.gov

Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

March 31, 2015

Conditions
Type 1 Diabetes
Interventions
DRUG

insulin delivery

Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.

DEVICE

glucose sensing

Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.

Trial Locations (1)

A-8036

Medical University of Graz, Graz

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Medical University of Graz

OTHER

NCT02359617 - Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration | Biotech Hunter | Biotech Hunter